⌘K
t
Diaceutics PLC announced on 29 October 2024 that Cheryl MacDiarmid, age 56, has joined its board as a Non-Executive Director. This appointment followed an announcement on 1 October 2024 and the completion of Nominated Adviser due diligence checks.
| Date | 29 Oct 2024 |
| Time | 10:27:39 |
| Category | Board changes |
| ID | 0622K |
Diaceutics PLC - Board Change Update
Belfast and London, 29 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces that following the announcement on 1 October 2024 and completion of the usual Nominated Adviser due diligence checks, Cheryl MacDiarmid is confirmed as having joined the board as a Non-Executive Director.
The following information is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies:
Additional information with regard to Cheryl MacDiarmid:
Cherly MacDiarmid (née Gaskin), age 56, is currently or has been a director of the following companies within the past five years:
|
Current Directorships |
Former Directorships |
|
Allergy Therapeutics Plc |
|
|
|
Phivco UK Limited |
|
|
ViiV Healthcare UK (NO.6) Limited |
|
|
ViiV Healthcare UK (NO.3) Limited |
|
|
ViiV Healthcare UK (NO.5) Limited |
|
|
ViiV Healthcare Trading Services UK Limited |
|
|
ViiV Healthcare UK (NO.4) Limited |
|
|
ViiV Healthcare Overseas Limited |
|
|
ViiV Healthcare UK (NO.7) Limited |
|
|
ViiV Healthcare Finance Limited |
|
|
ViiV Healthcare UK Limited |
|
|
Phivco UK II Limited |
|
Enquiries: Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 |
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.